ophthalmology Archives - Page 6 of 13 -

Kyowa Kirin has bought back rights outside of cancer to tivozanib, amending an agreement dating back to 2006

Could Kyowa Kirin be eyeing ophthalmology use for cancer drug tivozanib?

https://pharmaphorum.com/news/could-kyowa-kirin-be-eyeing-ophthalmology-use-for-cancer-drug-tivozanib/

News/ News/ R&D

Oxford Biomedica signs ophthalmology R&D deal with Santen

Richard Staines gene therapy, ophthalmology, Oxford Biomedica, R&D, santen 0 Comment

UK biotech Oxford Biomedica and Japan’s Santen have begun an option and licence agreement to research and develop

Oxford Biomedica signs ophthalmology R&D deal with Santen

https://pharmaphorum.com/news/oxford-biomedica-signs-ophthalmology-rd-deal-with-santen/

News/ News/ R&D

Bayer begins phase 3 trial testing aflibercept in infant blindness

Richard Staines Bayer, ophthalmology 0 Comment

Bayer has begun a late-stage trial of its blockbuster aflibercept eye drug to prevent blindness in premature infants.

Bayer begins phase 3 trial testing aflibercept in infant blindness

https://pharmaphorum.com/news/bayer-begins-phase-3-trial-testing-aflibercept-in-infant-blindness/

Partner Content/ Partner content/ Press releases

Registration opens for SMi’s 3rd Annual Ophthalmic Drugs Conference

Neill Howard Ocular, ophthalmology 0 Comment

Insights into Ophthalmology

Registration opens for SMi’s 3rd Annual Ophthalmic Drugs Conference

https://pharmaphorum.com/partner-content/registration-opens-for-smis-3rd-annual-ophthalmic-drugs-conference/

News/ News

NICE backs Alimera’s three-year uveitis implant

Phil Taylor alimera, NICE, ophthalmology, Rare diseases 0 Comment

An implant developed by Alimera Sciences has been recommended by NICE to treat an inflammatory eye disease that

NICE backs Alimera’s three-year uveitis implant

https://pharmaphorum.com/news/nice-backs-alimeras-three-year-uveitis-implant/

Events/ Events/ Partner Content

Ophthalmic Drugs Conference

Neill Howard Ocular, ophthalmology 0 Comment

SMi Group are pleased to present the 3rd Annual Ophthalmic Drugs Conference and Focus Day, taking place on

Ophthalmic Drugs Conference

https://pharmaphorum.com/events/ophthalmic-drugs-conference/

News/ News/ R&D

Novartis shows off pipeline – including 25 potential blockbusters

Richard Staines cancer, Novartis, ophthalmology, R&D, Rare diseases, respiratory 0 Comment

Novartis has showcased its pipeline at its annual meet-the-management day, where investors and analysts got to hear company

Novartis shows off pipeline – including 25 potential blockbusters

https://pharmaphorum.com/news/novartis-shows-off-pipeline-including-25-potential-blockbusters/

Digital/ News/ News

Ping An completes trial of AI-based retinal disease screening system

Richard Staines artificial intelligence, ophthalmology 0 Comment

Ping An Technology has announced it has completed a clinical trial of the world’s first intelligent optical coherence

Ping An completes trial of AI-based retinal disease screening system

https://pharmaphorum.com/news/ping-an-completes-trial-of-ai-based-retinal-disease-screening-system/

Janssen J&J Johnson and Johnson pharmaceutical companies

News/ News/ Oncology/ Top stories

J&J unveils top pipeline prospects, with main focus on cancer

Richard Staines cancer, gastroenterology, infectious diseases, inflammatory diseases, Johnson & Johnson, neurology, ophthalmology, R&D 0 Comment

Johnson & Johnson has shone the spotlight on the most promising drugs in its pipeline, saying it plans

J&J unveils top pipeline prospects, with main focus on cancer

https://pharmaphorum.com/news/jj-unveils-top-pipeline-prospects-cancer/

Trending

ophthalmology

Login